To Assess Efficacy of Epiitalis on Knee Pain in Patients Suffering From Knee Osteoarthritis

A Double Blind, Double Dummy, Dose Response, Randomized, Placebo Controlled Study to Assess the Efficacy of Epiitalis on Knee Pain in Patients Suffering From Knee Osteoarthritis

Epiitalis is an ingredient of a currently marketed product named as Osteo-Restore, indicated for joint health.The present study is primarily planned to establish the role of Epiitalis as a single ingredient in the treatment of mild to moderate cases of knee Osteoarthritis.

Inclusion Criteria:

1. Male & female aged ≥ 40 to ≤ 65 years suffering from primary idiopathic osteoarthritis of the knee diagnosed at least 3 months prior to screening.

2 BMI ≥ 18 and ≤ 29.9 kg/m2. 3 Fasting blood sugar ≤ 126 mg/dl 4 LFT: Serum Glutamic oxaloacetic transaminase (SGOT) & <2X Upper Limit of Normal (UNL) and Serum Glutamic-Pyruvic transaminase (SGPT) & <2X UNL.

5 Serum Creatinine & <1.5X UNL. 6 Index knee joint pain rated ≥ 60 on a 100-point Pain-Visual Analogue Scale (VAS).

7. Osteoarthritis grade II/ III (Kellgren-Lawrence classification) as confirmed by: Grade II - Definite osteophytes and possible joint space narrowing (JSN) on the anteroposterior weight-bearing radiograph Grade III - Multiple osteophytes, definite JSN, sclerosis, and possible bony deformity 8. Systolic blood pressure & <140 mmHg and diastolic blood pressure & < 90 mmHg 9. In the case of hypothyroidism, only euthyroid patients will be allowed to be screened further. Blood reports of last 3 months will be valid at the time of screening.

10. Female participants of childbearing age must be willing to use the accepted methods of contraception during the course of the study.

11. Participants should be willing to be involved in some

Exclusion Criteria:

1. History of osteoarthritis for more than 3 years.
2. History of osteoporosis and/or frequent fractures.
3. History of major trauma to the index joint.
4. History of arthroscopic surgery or intervention on the index joint or awaiting a replacement of knee or hip joint.
5. History of restless leg syndrome.
6. Participants who have received intra-articular steroids or hyaluronic acid within the last three months.
7. Not willing to abstain from the use of NSAIDs (including low dose aspirin 50 mg/day for cardiovascular health) or herbal/ nutraceutical supplements for joint health.
8. Not willing to abstain from application of local analgesics, herbal oil 48 hours prior to study visit.
9. Use of any immunosuppressive drugs in the last 12 months (including steroids).
10. Participants with deformity of the knee joint.
11. Participants categorized as ACR Functional Class I osteoarthritis
12. Participants who are significantly incapacitated or disabled and would be categorized as ACR Functional Class IV osteoarthritis (largely or wholly incapacitated), or unable to walk without assistive devices.
13. Participants with other known rheumatic or inflammatory diseases such as rheumatoid arthritis, osteomyelitis, and bone metastasis.
14. Current smokers or chronic alcoholics.
15. History of bleeding disorders.
16. Participants suffering from deep vein thrombosis.
17. Participants suffering from diabetic neuropathy.
18. History of major chronic hepatic, cardiovascular, neurological or immunosuppressive conditions or the presence of any infections.
19. Participants planning to travel in the next 56 days or engage in any non-routine activity that is likely to strain the knees.
20. Participants having a history of any malignancy.
21. Inability to comply with the protocol requirements.
22. Participation in any other clinical trial within 3 months of registering in this trial.
23. . Women of child-bearing potential with a positive pregnancy test or who are lactating.
24. Any other condition which in the opinion of the Investigator may jeopardize the study.